AnaptysBio Inc

NASDAQ:ANAB   3:59:57 PM EDT
26.84
-0.50 (-1.83%)
Products

FDA Grants Accelerated Approval Of Jemperli (Dostarlimab-Gxly) For Dmmr Recurrent Or Advanced Solid Tumors

Published: 08/17/2021 21:12 GMT
AnaptysBio Inc (ANAB) - FDA Grants Accelerated Approval of Jemperli (dostarlimab-gxly) for Dmmr Recurrent Or Advanced Solid Tumors.
Anaptysbio Inc - Anaptysbio Has Earned a $20 Million Milestone Payment As a Result of This Second FDA Approval for Jemperli.
Anaptysbio Inc - Anticipate Additional $15 Million & $165 Million Payments Upon Achievement of Certain Jemperli Regulatory and Commercial Milestones.
Anaptysbio - Royalties for Jemperli Range From 8% to 25% of Global Net Sales, Where Co Will Receive 8% of Annual Global Net Sales Below $1 Billion.
Anaptysbio - Royalties for Jemperli Range From 8% to 25% of Global Net Sales, Where Co Will Receive 12-25% of Annual Global Net Sales Above $1 Billion.